Bispecific binding proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-11279759-B2
Application number	US-201916570966-A
Country	US
Kind code	B2
Filing date	Sep 13, 2019
Priority date	May 6, 2016
Publication date	Mar 22, 2022
Grant date	Mar 22, 2022

Abstract

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

First claim

What is claimed is:

1. A bispecific binding protein that binds to PD-1 and TIM3 comprising a first heavy chain, a first light chain, a second heavy chain, and a second light chain,
wherein the first heavy chain comprises: a first heavy chain CDR1 comprising amino acids having the sequence set forth in residues 24-35 of SEQ ID NO: 9, a first heavy chain CDR2 comprising amino acids having the sequence set forth in residues 50-66 of SEQ ID NO: 9, and a first heavy chain CDR3 comprising amino acids having the sequence set forth in residues 99-111 of SEQ ID NO: 9;
wherein the first light chain comprises: a first light chain CDR1 comprising amino acids having the sequence set forth in residues 24-41 of SEQ ID NO: 7, a first light chain CDR2 comprising amino acids having the sequence set forth in residues 55-61 of SEQ ID NO: 7, and a first light chain CDR3 comprising amino acids having the sequence set forth in residues 94-100 of SEQ ID NO: 7;
wherein the second heavy chain comprises: a second heavy chain CDR1 comprises SEQ ID NO: 79, a second heavy chain CDR2 comprises SEQ ID NO: 80, a second heavy chain CDR3 comprises SEQ ID NO: 81; and
wherein the second light chain comprises: a second light chain CDR1 comprises SEQ ID NO: 82, the second light chain CDR2 comprises SEQ ID NO: 83, the second light chain CDR3 comprises SEQ ID NO: 84.

2. The bispecific binding protein of claim 1 , wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 9, wherein the first light chain comprises the amino acid sequence of SEQ ID NO: 7, wherein the second heavy chain comprises the amino acid sequence of SEQ ID NO: 30, and wherein the second light chain comprises the amino acid sequence of SEQ ID NO: 28.

3. An antibody or antigen binding fragment thereof that binds to TIM3 comprising a heavy chain comprising CDR1, CDR2, and CDR3 and a light chain comprising CDR1, CDR2, and CDR3, wherein the heavy chain CDR1 comprises SEQ ID NO: 79, the heavy chain CDR2 comprises SEQ ID NO: 80, the heavy chain CDR3 comprises SEQ ID NO: 81, and the light chain CDR1 comprises SEQ ID NO: 82, the light chain CDR2 comprises SEQ ID NO: 83, the light chain CDR3 comprises SEQ ID NO: 84.

4. The antibody or antigen binding fragment thereof of claim 3 , comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: SEQ ID NO: 85, and the light chain variable region comprises: SEQ ID NO: 86.

5. The antibody or antigen binding fragment thereof of claim 3 , wherein the heavy chain comprises SEQ ID NO: 87, and the light chain comprises: SEQ ID NO: 88.

6. A composition comprising the bispecific binding protein of claim 2 and a pharmaceutically acceptable carrier.

7. A nucleic acid molecule comprising a nucleotide sequence encoding the bispecific binding protein according to claim 2 .

8. A vector comprising the nucleic acid molecule of claim 7 .

9. A host cell comprising the vector of claim 8 .

10. A method of treating cancer in a subject, the method comprising administering the bispecific binding protein of claim 2 to the subject.

11. The method of claim 10 , wherein the cancer is one or more of ovarian cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, uterine cancer, testicular cancer, bladder cancer, head and neck cancer, melanoma, pancreatic cancer, renal cell carcinoma, and lung cancer.

12. A method of enhancing an immune response in a subject, the method comprising administering the bispecific binding protein of claim 2 to the subject.

13. A composition comprising the bispecific binding protein of claim 1 and a pharmaceutically acceptable carrier.

14. A nucleic acid molecule comprising a nucleotide sequence encoding the bispecific binding protein according to claim 1 .

15. A vector comprising the nucleic acid molecule of claim 14 .

16. A host cell comprising the vector of claim 15 .

17. A method of treating cancer in a subject, the method comprising administering the bispecific binding protein of claim 1 to the subject.

18. The method of claim 17 , wherein the cancer is one or more of ovarian cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, uterine cancer, testicular cancer, bladder cancer, head and neck cancer, melanoma, pancreatic cancer, renal cell carcinoma, and lung cancer.

19. A method of enhancing an immune response in a subject, the method comprising administering the bispecific binding protein of claim 1 to the subject.

Assignees

• Medimmune Llc

Inventors

• Kasturirangan Srinath
• Gao Changshou
• Rainey Godfrey
• Morrow Michelle
• Dobson Claire Louise
• Drabic Stacey
• Schofield Darren
• Carlesso Gianluca
• Pollizzi Kristen
• Mazor Yariv
• Oberst Michael
• Hammond Scott A
• Lobo Brian
• Manikwar Prakash
• Seaman Jonathan
• Dovedi Simon
• Herbst Ronald

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/77

  Internalization into the cell · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title